{
    "clinical_study": {
        "@rank": "60470", 
        "arm_group": [
            {
                "arm_group_label": "Ticagrelor 180 mg single dose", 
                "arm_group_type": "Active Comparator", 
                "description": "Ticagrelor 180 mg single dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo single dose"
            }
        ], 
        "brief_summary": {
            "textblock": "Preclinical studies have shown that the P2Y12 receptor antagonist ticagrelor can increase\n      the extracellular concentration of the endogenous nucleoside adenosine by inhibiting the\n      cellular uptake of adenosine via the equilibrative nucleoside transporter (ENT). This\n      mechanism can contribute to the beneficial effects and to the side effects (dyspnea) of\n      ticagrelor in patients with an acute myocardial infarction. In the current research\n      proposal, we aim to investigate whether ticagrelor increases adenosine receptor stimulation\n      in humans in vivo by ENT inhibition."
        }, 
        "brief_title": "Ticagrelor and Adenosine", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male sex\n\n          -  Age 18-40 years\n\n          -  Healthy\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Smoking\n\n          -  Hypertension (Blood pressure >140 mmHg and/or >90 mmHg - SBP/DBP-)\n\n          -  Diabetes Mellitus (fasting glucose > 7.0 mmol/L or random > 11.0 mmol/L)\n\n          -  History of any cardiovascular disease\n\n          -  History of chronic obstructive pulmonary disease (COPD) or asthma\n\n          -  Bleeding tendency\n\n          -  Concomitant use of medication\n\n          -  Renal dysfunction (MDRD < 60 ml/min)\n\n          -  Liver enzyme abnormalities (ALAT > twice upper limit of normality)\n\n          -  Thrombocytopenia (<150*109/ml)\n\n          -  Second/third degree AV-block on electrocardiography"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996735", 
            "org_study_id": "NL43379.091.13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ticagrelor 180 mg single dose", 
                "intervention_name": "Ticagrelor 180 mg single dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Adenosine", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Endothelial function", 
            "Adenosine receptor stimulation"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nijmegen", 
                    "country": "Netherlands", 
                    "state": "Gelderland", 
                    "zip": "6500 HB"
                }, 
                "name": "Radboud University Nijmegen Medical Centre"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Ticagrelor on the Adenosine System", 
        "overall_official": [
            {
                "affiliation": "Radboud University", 
                "last_name": "N. Riksen, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Radboud University", 
                "last_name": "G. Rongen, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dept Cardiology, Canisius Wilhelmina Hospital Nijmegen", 
                "last_name": "M. Gomes, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Radboud University", 
                "last_name": "S. El Messaoudi, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Forearm blood flow response to the intrabrachial administration of incremental dosages of adenosine, after treatment with ticagrelor compared to placebo. The forearm blood flow will be measured by plethysmography.", 
                "measure": "Forearm blood flow response", 
                "safety_issue": "No", 
                "time_frame": "2 hours after intake of ticagrelor/placebo"
            }, 
            {
                "description": "Directly after 2 and 5 minutes of forearm ischemia.The forearm blood flow will be measured by plethysmography.", 
                "measure": "Forearm blood flow response", 
                "safety_issue": "No", 
                "time_frame": "Directly after 2 and 5 minutes of forearm ischemia"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996735"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Forearm blood flow response to the intrabrachial administration of incremental dosages of dipyridamole, after treatment with ticagrelor compared to placebo. The forearm blood flow will be measured by plethysmography", 
                "measure": "Forearm blood flow respons", 
                "safety_issue": "No", 
                "time_frame": "Directly after administration of dipyridamole"
            }, 
            {
                "description": "To study whether ticagrelor inhibits the ex-vivo adenosine uptake in isolated erythrocytes", 
                "measure": "ex-vivo adenosine uptake in isolated erythrocytes", 
                "safety_issue": "No", 
                "time_frame": "2 hours after intake of studymedication"
            }
        ], 
        "source": "Radboud University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Radboud University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}